Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70494 ↗Kurz gefasst
Scoping Review in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Bahareh Abtahi-Naeini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Dermatology Division, Department of Pediatrics, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Dapsone, Skin Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dapsone (4,4′‐Diamino diphenyl sulfone) has been utilized in managing a wide variety of mucocutaneous conditions, usually as a systemic product. Topical dapsone is commercially available as 5% and 7.5% gel and is FDA‐approved for acne vulgaris. These topical formulations have shown less systemic absorption and fewer adverse events. Considering this, topical dapsone might benefit localized disease, immunosuppressed individuals, and those who avoid exposure to systemic therapies.
Methods
Following PRISMA guidelines, a comprehensive literature search was conducted across PubMed, Web of Science, and Scopus databases for published papers up to April 2025. Then, eligible studies are included, and we summarize the findings of different clinical studies concerning the use, efficacy, and side effects of topical dapsone in various mucocutaneous conditions, excluding acne vulgaris.
Results
Finally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others.
Conclusion
In conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Dermatology Division, Department of Pediatrics, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
- Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- Clinical Research Development Center, Najafabad Branch, Islamic Azad University, Najafabad, Iran.
- Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran.
- Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
ORCID-Profile: Bahareh Abtahi-Naeini, Hossein Sattari, Kimia Afshar, Fereshte Rastegarnasab, Mahsa Pourmahdi-Boroujeni
Zitieren
APA
Abtahi-Naeini, B., Sattari, H., Afshar, K., Rastegarnasab, F., & Pourmahdi-Boroujeni, M. (2025). Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70494
Vancouver
Abtahi-Naeini B, Sattari H, Afshar K, Rastegarnasab F, Pourmahdi-Boroujeni M. Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70494
BibTeX
@article{AbtahiNaeini2025,
author = {Abtahi-Naeini, Bahareh and Sattari, Hossein and Afshar, Kimia and Rastegarnasab, Fereshte and Pourmahdi-Boroujeni, Mahsa},
title = {Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70494}
}
EUVIMED